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Systemic hypotension in preterm infants has been related to increased mortality,
cerebrovascular lesions, and neurodevelopmental morbidity. Treatment of hypotension
with inotropic medications aims at preservation of end organ perfusion and oxygen
delivery, especially the brain. The common inotropic medications in preterm infants include
dopamine, dobutamine, adrenaline, with adjunctive use of corticosteroids in cases of
refractory hypotension. Whether maintenance of mean arterial blood pressure (MAP)
by use of inotropic medication is neuroprotective or not remains unclear. This review
explores the different inotropic agents and their effects on perfusion and oxygenation
in the preterm brain, in clinical studies as well as in animal models. Dopamine and
adrenalin, because of their α-adrenergic vasoconstrictor actions, have raised concerns of
reduction in cerebral blood flow (CBF). Several studies in hypotensive preterm infants
have shown that dopamine elevates CBF together with increased MAP, in keeping with
limited cerebro-autoregulation. Adrenaline is also effective in raising cerebral perfusion
together with MAP in preterm infants. Experimental studies in immature animals show
no cerebro-vasoconstrictive effects of dopamine or adrenaline, but demonstrate the
consistent findings of increased cerebral perfusion and oxygenation with the use of
dopamine, dobutamine, and adrenaline, alongside with raised MAP. Both clinical and
animal studies report the transitory effects of adrenaline in increasing plasma lactate,
and blood glucose, which might render its use as a 2nd line therapy. To investigate the
cerebral effects of inotropic agents in long-term outcome in hypotensive preterm infants,
carefully designed prospective research possibly including preterm infants with permissive
hypotension is required. Preterm animal models would be useful in investigating the
relationship between the physiological effects of inotropes and histopathology outcomes
in the developing brain.
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INTRODUCTION
Systemic hypotension is a relatively common complication of
preterm birth, affecting approximately one-third of very low
birth weight infants. Systemic hypotension has been associated
with increased mortality, intraventricular hemorrhage, periven-
tricular leukomalacia, and neurodevelopmental morbidity in the
preterm infant (Miall-Allen et al., 1987; Watkins et al., 1989;
Goldstein et al., 1995; Cunningham et al., 1999), although a causal
relationship has yet to be established. Given the risks of hypoten-
sion, preterm infants identified as “hypotensive” often receive
treatments to elevate the blood pressure, with 16–52% receiv-
ing volume expansion (Al-Aweel et al., 2001) and up to 53%
(Laughon et al., 2007) receiving inotropic agents for hypoten-
sion, with the most common drugs of choice being dopamine,
dobutamine, and adrenaline.
Several studies have shown that systemic hypotension is asso-
ciated with reduced end-organ perfusion, low cerebral blood
flow (CBF), and cerebral oxygen delivery, which are presumably
the mechanism for the adverse neurodevelopmental outcome
associated with hypotension (Lou et al., 1977; Tsuji et al., 2000;
Munro et al., 2004). Therefore, the main goal for maintain-
ing mean arterial blood pressure (MAP) in preterm infants is
to preserve organ perfusion and oxygen delivery, particularly
the brain. However, the inotropic medications selected to raise
MAP are obviously those which are known to act primarily on
the cardiovascular system, their effects on the cerebral vascu-
lature and oxygen delivery are less known. In this review, we
have described and synthesized the research literature, in both
animal and clinical studies, on the impact of inotropic agents
on cerebral perfusion and oxygenation in the preterm brain. We
have also identified the knowledge gap in the literature, and the
future research required to address the issues and inform clinical
practice.
EFFECTS/IMPLICATION OF HYPOTENSION IN PRETERM
INFANTS
Although there are epidemiological data for “normative” blood
pressure values in preterm infants, the ranges of normal blood
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pressure where adequate organ perfusion is ensured for different
gestational and postnatal ages remain unclear. Several studies
have attempted to create reference ranges for blood pressure in
neonates based on birthweight, gestational age, and/or postna-
tal age (Watkins et al., 1989; Cunningham et al., 1999; Lee et al.,
1999). Data from these studies provided support for the com-
monly cited “rule of thumb” that defines hypotension as MAP
below an infant’s gestational age in weeks, using the lower 90%
confidence interval of MAP as the threshold for hypotension
(BAPM, 1998; Cunningham et al., 1999). Hypotensive infants
will often receive treatment for restoration of MAP to the tar-
get reference range, as many studies have found that systemic
hypotension is associated with increased brain injury and poor
neurodevelopmental outcome (Goldstein et al., 1995; Seri and
Evans, 2001). The brain of the preterm infants is particularly
vulnerable to decreases in perfusion pressure, as several reports
(Munro et al., 2004; Wong et al., 2008) have found impaired
cerebral autoregulation in preterm infants. The direct variation
of CBF and MAP in preterm infants implies hypotension would
lead to low CBF and the risk of hypoxic-ischemic brain injury.
The risk is accentuated in the preterm white matter, possibly
related to the development of the vascular supply to these regions.
The cerebral white matter is supplied by long and short pen-
etrating arteries, and the distal fields of these vessels are not
yet fully developed in the preterm brain, thus forming vascu-
lar end zones where perfusion is thought to be relatively close
to the metabolic demand (Takashima and Tanaka, 1978; Volpe,
2001). The preterm cerebral white matter at these vascular end
zones are most sensitive to falls in cerebral perfusion pressure
(Borch et al., 2010), and it is therefore widely thought that these
zones would suffer from severe ischemia with decreases in CBF.
In addition, CBF is markedly lower in the preterm white mat-
ter compared to the cortical gray matter (Borch and Greisen,
1998), further increasing the vulnerability of the white matter to
hypoxic-ischemic injury. Also, an association between hypoten-
sion and cerebrovascular lesions has been described (Miall-Allen
et al., 1987; Watkins et al., 1989; Bada et al., 1990; Cunningham
et al., 1999), supporting the notion that cerebral ischemic injury
occurs secondary to failure of autoregulation to maintain CBF
during hypotension. The implication is that pharmacological
manipulation of systemic blood pressure is likely to affect cerebral
perfusion pressure and CBF.
While systemic hypotension in preterm infants is often rig-
orously treated with the goal of restoring CBF and minimizing
cerebral injury, the association between treatment of hypoten-
sion and improved outcome is still controversial (Cunningham
et al., 1999; Limperopoulos et al., 2007). Whether maintenance of
MAP by use of inotropic medication is neuroprotective, or indeed
might lead to cerebral compromise, remains unclear. There is no
evidence that treatment of systemic hypotension results in short-
or long-term improvement of neurological outcomes (Dempsey
and Barrington, 2007), and such evidence could be obtained
only carefully designed prospective studies. It is also not known
whether the use of dopamine, dobutamine, or adrenaline as
the first-line vasoactive/inotropic agent, in the treatment of the
hypotensive preterm infant, offers an advantage over each other
in improving outcome.
BLOOD PRESSURE MANAGEMENT IN PRETERM INFANTS
There is considerable variation between neonatal centers in the
reported prevalence of hypotension, the threshold for therapeutic
intervention, and the choice of cardiovascular support (Al-Aweel
et al., 2001). In a cohort of 1507 infants born between 23 and
27 weeks of gestational age at 14 centers (Laughon et al., 2007),
the proportion of infants who received inotropic medication for
hypotension varied between 6 and 64% in the different cen-
ters, and uniform thresholds of blood pressure for commencing
inotropic treatment were not apparent. The inter-center varia-
tions could not be explained by variations in infant character-
istics, and are more likely to reflect differences in care practices
(Laughon et al., 2007).
The most commonly employed therapies are volume expan-
sion, followed by use of inotropic agents if hypotension per-
sists. Volume expansion with colloid or crystalloid is frequently
used as a first-line treatment in neonatal hypotension. Even in
the absence of hypovolemia, volume expansion has the poten-
tial to increase cardiac output and blood pressure through
the Frank–Starling mechanism and may therefore be a use-
ful therapeutic strategy to avoid use of inotropic medications
(Subhedar, 2003). It is less effective than inotropic medications
at increasing blood pressure (Lundstrom et al., 2000). In cases
of refractory or vasopressor-resistant hypotension, corticosteroid
is often added as an adjunctive therapy (see below for further
discussion).
Dopamine is the most commonly used inotropic medication
in the treatment of neonatal hypotension. It is an endogenous cat-
echolamine precursor of noradrenaline with sympathomimetic
properties. It exerts cardiovascular effects through direct stim-
ulation of dopaminergic, adrenergic and serotonic receptors, or
indirectly by stimulating adrenergic receptors though its conver-
sion to noradrenaline in sympathetic nerve endings (Subhedar,
2003). The cardiovascular actions of dopamine depend on
the overall balance of dopaminergic, α- and β-receptors ago-
nist activity, and are likely to be dose-related. The increase
in systemic blood pressure following dopamine administra-
tion is thought to be a result of arterial vasoconstriction and
increased cardiac output (Seri and Evans, 2001). There is wide
inter-individual variation in the blood pressure response to
dopamine infusion, but whether this reflects differences in
plasma concentration, underlying pathophysiology, or periph-
eral vs. cardiac actions remain unknown. Most hypotensive
infants respond to doses of 2.5–20μg.kg−1.min−1, with vast
majority of very low-birthweight infants responding to doses
<10μg.kg−1.min−1(Gill and Weindling, 1993; Roze et al., 1993;
Lundstrom et al., 2000). Treatment of neonates with high-
dose dopamine (>20μg.kg−1.min−1) is usually avoided because
of concerns regarding excessive α-receptor-mediated peripheral
vasoconstriction, with a corresponding reduction in cardiac out-
put (Roze et al., 1993). Addition of another agent such as dobu-
tamine is preferred by many clinicians. On the other hand, there
is no evidence that, when required to normalize blood pressure,
high-dose dopamine treatment has detrimental vasoconstrictive
effects (Seri and Noori, 2005).
Dobutamine is a synthetic analogue of isoprenaline with
some chemical similarities to dopamine. Dobutamine stimulates
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both α- and β-adrenergic receptors but is relatively selective
for cardiac β-1 receptors for its inotropic effects, with lower
affinity for peripheral α-1 and β-2 receptors (Crocker, 1994).
In neonates, positive effects on left ventricular performance at
dobutamine doses of 5–10μg.kg−1.min−1(Stopfkuchen et al.,
1987) and increases systemic blood flow, as measured by flow in
the superior vena cava (SVC), at doses of 10–20μg.kg−1.min−1
have been demonstrated (Osborn et al., 2002). Randomized
trials comparing the effectiveness of dopamine versus dobu-
tamine in increasing blood pressure showed that dobutamine
was less effective than dopamine at increasing blood pressure
in hypotensive preterm infants (Subhedar and Shaw, 2003).
However, dobutamine has a superior effect in maintaining left
ventricular output in these infants (Roze et al., 1993; Subhedar
and Shaw, 2003). No significant difference was found between
the effects of dopamine and dobutamine for infant mortal-
ity, or the incidence of cerebrovascular lesions. However, the
impact of dopamine compared to dobutamine, when used as
inotropic agents for blood pressure support, on long-term neu-
rodevelopmental outcome is still uncertain (Subhedar and Shaw,
2003).
Systemic blood flow, as Doppler measurement of SVC flow,
has been proposed to be an index of brain perfusion and a
low SVC flow of <41ml/kg/min as the threshold for commenc-
ing inotropic medications (Kluckow and Evans, 2000a,b; Osborn
et al., 2002). When SVC flow was used as the treatment cri-
teria and the outcome measure, dobutamine was found to be
more effective than dopamine in raising SVC flow (Osborn et al.,
2002). However, the relationship between SVC flow and CBF is
complex because SVC flow includes venous return from many
extracerebral vascular beds and in which the regulation of blood
flow may differ significantly from that of brain, especially in
pathophysiological conditions. For example, with hypovolemia
and hypotension, peripheral vasoconstriction occurs to main-
tain systemic blood pressure and cerebral perfusion pressure,
while cerebral vasodilatation occurs to increase CBF (Malcus
et al., 1991). The opposite changes in peripheral and CBF thus
render interpretation of SVC flow difficult. Long-term effect
of inotropic treatment in infants with low SVC flow is also
unclear. In a randomized controlled trial in which infants with
low SVC flow were treated with dopamine or dobutamine, there
was a trend toward increased death in the dobutamine group;
there was a trend toward increased neurodevelopmental disabil-
ity in the dopamine group. However, the study was difficult to
interpret because of the absence of a control group of infants
with untreated low SVC flow for comparison (Osborn et al.,
2007).
Milrinone is a selective inhibitor of type III cAMP phospho-
diesterase isoenzyme in cardiac and vascular muscle. It has both
positive inotrope and vasodilator effects (Chang et al., 1995).
Milrinone has been used therapeutically (Chang et al., 1995;
Ramamoorthy et al., 1998; Duggal et al., 2005) and prophylac-
tically (Hoffman et al., 2003) to improve low cardiac output in
infants after cardiac surgery. However, a main adverse effect of
milrinone is actually hypotension, which usually precludes its use
alone in the setting of neonatal hypotension. Milrinone was tri-
aled as a prophylactic treatment to prevent low SVC flow in very
preterm infants but was found not to be effective (Paradisis et al.,
2009).
Adrenaline (epinephrine) is often used as a second or third
line of treatment in systemic hypotension, usually in addition
to dopamine and/or dobutamine infusion. Adrenaline acts upon
α1-, β1- and β2-adrenergic receptors. In a randomized con-
trol trial in very low-birthweight infants with early postnatal
hypotension, in whom either adrenaline or dopamine infusion
was administered (Valverde et al., 2006), low-dose adrenaline
is as effective as low/moderate-dose dopamine in increasing
systemic MAP and has a more intense chronotropic effect.
Importantly, the adrenaline-treated infants did not differ with
respect to short- and medium-term outcomes including neu-
rodevelopment, when compared with dopamine-treated infants
(Pellicer et al., 2009). Furthermore, infants who gained a nor-
malized blood pressure with either dopamine or adrenaline
had neurodevelopmental outcomes comparable with those of
control normotensive infants (Pellicer et al., 2009). However,
adrenaline has the transitory effect of increasing plasma lac-
tate, blood glucose and the need for insulin therapy (Valverde
et al., 2006), probably due to β2-adrenoreceptor stimulation,
which therefore raises concern about the use of adrenaline as a
first-line inotrope in preterm infants prone to such metabolic
disturbances.
Although the majority of preterm neonates will achieve blood
pressure values perceived to be normal with volume expansion,
vasopressor and/or inotrope administration, up to a quarter
of all very low birth weight neonates treated for hypoten-
sion do not respond to moderate-to-high dose of vasopressor
administration (Ng et al., 2004). The etiology of vasopressor-
resistant hypotension is thought to be a combination of transient
adrenocortical insufficiency of prematurity and downregula-
tion of the cardiovascular adrenergic receptors (Seri, 2006a). In
these patients, blood pressure may increase with corticosteroid
administration. Raised corticosteroid levels increase intracellu-
lar calcium availability in the cardiovascular system, leading to
increased myocardial and vascular smooth muscle cell contractil-
ity in response to catecholamines (Wehling, 1997). Corticosteroid
would also act via enhancement of adrenergic, dopaminergic, and
angiotensin II receptor expression, thus sensitizing the cardio-
vascular system to endogenous and exogenous catecholamines.
In preterm infants who develop vasopressor dependence or
vasodepressor-resistant hypotension, low doses of hydrocortisone
have been shown to result in improvement of blood pressure
without compromising cardiac function or systemic perfusion
and therefore allow vasopressor support to be reduced over
the next 24–72 h (Helbock et al., 1993; Ng et al., 2001; Seri
and Evans, 2001; Ng et al., 2004; Seri and Noori, 2005; Seri,
2006a,b). Unlike dexamethasone, hydrocortisone has not been
shown to be associated with neurodevelopmental delay or cere-
bral palsy (Lodygensky et al., 2005; Karemaker et al., 2006;
Rademaker et al., 2007). However, caution must be exercised
as available data suggest that co-exposure of hydrocortisone
and indomethacin in the first postnatal week, in very preterm
infants being treated for patent ductus arteriosus, increases the
risk of spontaneous intestinal perforation (Watterberg et al.,
2004).
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SPECIFIC CEREBRAL EFFECTS OF INOTROPIC AGENTS IN
THE IMMATURE BRAIN (TABLE 1)
CEREBRAL BLOOD FLOW IN PRETERM INFANTS TREATED WITH
INOTROPIC AGENTS
The effect of dopamine on maintaining CBF has been the subject
of many clinical and experimental studies; however, no consensus
has been reached regarding the efficacy or safety of dopamine
administration for this purpose (Munro et al., 2004; Paradisis
et al., 2009). Because of its α-adrenergic vasoconstrictor actions,
there has been concern that dopamine might exert a direct
vasoconstrictor effect on the immature cerebral vasculature, so
impairing CBF (Munro et al., 2004). Such an effect would be com-
pounded by the already inadequate perfusion and oxygen delivery
to the brain that may be the result of the pre-existing hypoten-
sion. However, several studies in hypotensive preterm infants have
shown that dopamine elevates CBF together with increased MAP,
consistent with the limited autoregulation of CBF that is char-
acteristic of infants at this age (Seri et al., 1993; Munro et al.,
2004; Pellicer et al., 2005; Wong et al., 2008). The increase in
CBF following dopamine administration was greater in hypoten-
sive preterm infants compared to normotensive infants, possibly
because the hypotensive infants might have more severe impair-
ment of CBF autoregulation (Seri et al., 1993, 1998; Zhang et al.,
1999; Lundstrom et al., 2000; Jayasinghe et al., 2003; Munro et al.,
2004).
A randomized clinical study comparing dopamine- and
adrenaline-treated hypotensive preterm infants revealed that low-
dose adrenaline or low/moderate-dose dopamine both raised
cerebral perfusion, cerebral blood volume (CBV), and oxy-
genation (Pellicer et al., 2005). Notably, the CBV and cerebral
intravascular oxygenation increased in parallel, suggestive of a
vasodilatory effect on cerebral vasculature, and/or the recruit-
ment of unperfused capillaries (Pellicer et al., 2005).
ANIMAL STUDIES INVESTIGATING CEREBRAL BLOOD FLOWWITH
INOTROPIC AGENTS
In adult animal studies, dopamine infusion was shown to result in
cerebral vasodilation with increased CBF (Von Essen, 1974). In
anesthetized adult sheep (Myburgh et al., 2002), epinephrine,
norepinephrine, and dopamine all increased CBF from baseline,
together with increase in blood pressure, but this is likely to be
due to anesthesia-related autoregulatory impairment. In contrast,
in the awake adult sheep (Myburgh et al., 2002), cerebral autoreg-
ulation preserves a relatively constant CBF despite the increase
in systemic blood pressure with epinephrine or norepinephrine
infusion. However, of great importance is that CBF still increased
with dopamine infusion in these awake sheep studies despite
the presence of autoregulation (Myburgh et al., 2002), suggest-
ing that dopamine does have a cerebrovascular dilatatory effect
in addition to its inotropic action in increasing blood pressure.
Nevertheless, cerebrovascular response in the immature brain
may be different due to the ontogenic changes in cerebrovas-
cular receptor sensitivity to catecholamines, which suggest that
α-adrenergic receptor expression precedes that of β-adrenergic
receptors and, finally, dopaminergic receptors (Von Essen, 1974;
Edvinsson et al., 1979; Von Essen et al., 1980; Wagerle et al., 1990;
Gleason et al., 2002) Wagerle et al. studied the pial arteriolar
diameter decrease in response to norepinephrine and showed
that preterm fetal lambs are significantly more sensitive to nore-
pinephrine than full-term fetuses and newborn lambs, and that
adult cerebral arterioles are refractory to the presence of nore-
pinephrine (Wagerle et al., 1990). Gleason et al. also studied
preterm fetal lambs and found that dopaminergic receptor block-
ade had no effect on the autoregulatory responses to dopamine,
and the responses were completely blocked during α-adrenergic
receptor blockade (Gleason et al., 2002). Hence, in the immature
brain, it is possible that exogenous dopamine stimulates vasocon-
strictor α-adrenergic receptors, and the vasodilator dopaminergic
effects are minimal.
Nevertheless, studies using preterm and term newborn ani-
mal models, mainly lambs and piglets, have not shown that
dopamine produces cerebral vasoconstriction or reduced CBF
with dopamine infusion. Gleason et al. (2002) reported that
in well and unanesthetized preterm and near-term fetal lambs,
dopamine infusion up to 75μg/kg/min caused no change in
CBF and cerebral oxygen delivery despite an increase in MAP,
suggestive of an appropriate cerebral autoregulatory response to
the increased systemic blood pressure. Another study from the
same group using a similar preterm fetal lamb model found
that dopamine administration did not affect cerebral vasodilatory
responses to severe hypoxia (Mayock et al., 2007).
A more recent study using newborn anesthetized piglets inves-
tigated the dose-dependant effects of five inotropes (dopamine,
adrenaline, noradrenaline, dobutamine, and milrinone) on cere-
bral hemodynamic and oxygenation responses and identified
significant differences in these responses to specific drugs and
doses (Nachar et al., 2011). Low to medium doses of dopamine,
adrenaline, dobutamine, and noradrenaline all increased blood
pressure, common carotid blood flow, and cerebral oxygenation
(measured by near infrared spectroscopy), whereas milrinone
exerted minimal effects. However, this finding may in part be due
to the anesthesia-induced impairment of cerebral autoregulation,
leading to the parallel changes in blood pressure and CBF (Dagal
and Lam, 2009). At higher doses, dopamine, adrenaline, and
noradrenaline but not dobutamine decreased regional oxygena-
tion in kidney, intestinal, and muscle, while cerebral oxygenation
remained increased compared to baseline. The findings suggest an
α-adrenoreceptor-mediated peripheral vasoconstriction resulting
in a decrease in cardiac output and regional blood flow, but with
a relative sparing of the cerebral vasculature from vasoconstric-
tion. Consistent with a study in preterm infants (Pellicer et al.,
2005), adrenaline also induced significant increases in muscle
blood flow, serum glucose, and lactate concentrations in the new-
born piglets, effects that would make it unfavorable as a first-line
treatment. Another study comparing dopamine and dobutamine
infusion in term and preterm piglets (Ferrara et al., 1995) showed
that dopamine generated dose-dependent increases in CBF in
both preterm and term piglet groups, an effect produced by
dobutamine only in the term animals.
Overall, the results from animal studies are consistent with
the findings of a recent meta-analysis showing increased CBF
in preterm human studies receiving dopamine (Sassano-Higgins
et al., 2011). No studies in preterm human infants or exper-
imental preterm animal studies have demonstrated evidence
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that dopamine or adrenaline administration leads to excessive
cerebro-vasoconstriction, reduced CBF or cerebral oxygenation.
CEREBRAL METABOLIC RATE WITH DIFFERENT INOTROPIC AGENTS
It is important to also consider cerebral metabolic rate when
assessing the impact of changes in CBF. The balance between
cerebral oxygen consumption and delivery determines the oxygen
extraction and the overall cerebral tissue oxygenation. The effect
of inotropic agents on cerebral metabolic rate in the preterm
brain remains unknown. In the mature brain, it is generally
accepted that monoamines (including catecholamines) do not
cross the blood–brain barrier (BBB) (Emilien et al., 1999) and
therefore have minimal influence on the cerebral tissue and cere-
bral metabolic rate (Myburgh et al., 2002). In studies using adult
animal, when monoamines are administered in such a manner
that the BBB is bypassed (by intraventricular injection or intrac-
arotid infusion following induced BBB disruption), stimulation
and increase of cerebral metabolism is noted and accompanied,
probably secondarily, by a large increase in CBF (Mackenzie
et al., 1976). Specific stimulation of cerebral dopaminergic recep-
tors in adult baboons also results in increases in CBF which are
always accompanied by increase in cerebral oxygen consump-
tion (McCulloch and Harper, 1977), suggesting that the primary
result of cerebral dopaminergic stimulation might be to increase
cerebral metabolism, with CBF rising as a consequence of this
metabolic effect.
Endogenous dopamine has also been proposed to play a
fundamental role in the neurovascular regulation required for
flow-metabolism coupling in the primate brain (Iadecola, 1998;
Krimer et al., 1998). Association of dopamine therapy with
an improved flow-metabolism coupling response has also been
reported in a study in preterm infants (Wong et al., 2009).
Accordingly, increase in cerebral perfusion with dopamine infu-
sion may also be due to improved flow-metabolism coupling
response in the preterm brain, in addition to the increased
cerebral metabolic rate. These findings are relevant in the set-
ting of intravenous dopamine therapy in preterm infants where
there is evidence that the immature BBB allows access of exoge-
nous dopamine to cerebral parenchyma (Seri et al., 1984).
While the increase in CBF by dopamine reported in preterm
infants may represent an impaired autoregulatory response to
dopamine-induced increase in systemic blood pressure, the CBF
rise may also be secondary to a dopamine-induced increase in
cerebral metabolism as a flow-metabolism coupling response
(Busija and Heistad, 1984). Similar mechanisms may also under-
lie the increase in CBF observed in preterm infants receiving
adrenaline infusion (Pellicer et al., 2005) and would require
further investigation.
While little is known about the effect of inotropic agents on
cerebralmetabolic rate in the preterm brain, dobutamine infusion
was found to raise systemic metabolic rate and oxygen consump-
tion in newborn lambs (1–2 days old, 7–8 days old, and 6–8
weeks old lambs) (Penny et al., 2001). The finding is consistent
with studies in adults, in which catecholamines elevate the rest-
ing metabolic rate and systemic oxygen consumption (Chiolero
et al., 1991). In newborn lambs receiving dobutamine infusion
(Penny et al., 2001), systemic blood flow and oxygen delivery were
elevated as well as increased oxygen consumption but was most
apparent in 1–2 days old lambs. Importantly, this rise in oxy-
gen consumption in 1–2 days old lambs was 7–12-fold greater
than increases in the older lambs, outweighed the increase in
systemic oxygen delivery and was associated with increase in oxy-
gen extraction. It remains unknown whether similar effects of
dobutamine and/or other catecholamines would also occur in the
neonatal brain to raise cerebral metabolic rate and increase cere-
bral oxygen extraction; with such effects being most pronounced
in the more immature brain of younger gestational age. This
notion has important implications for the preterm brain injury, as
offsetting the balance between cerebral oxygen consumption and
delivery with high oxygen extraction may lead to cerebral hypoxia
in the extreme case.
FUTURE RESEARCH
There is a distinct lack of prospective research addressing cerebral
effects of inotropic treatments in preterm infants and their
long-term outcome (Shuhaiber et al., 2004). This is understand-
able given the ethical difficulty in setting up a clinical trial in
which hypotensive preterm infants are randomized to receive
either inotropic medications or placebo. While several animal
and clinical studies have found short-term increase in CBF
and cerebral oxygenation with use of inotropic medications,
information of inotropic medications in relation to long-term
outcome has mainly come from retrospective studies in infants
treated for cardiovascular compromise. These are limited and as
yet inconclusive due to the confounding effects of the more severe
clinical illness and underlying pathologies in the hypotensive
infants (Fanaroff et al., 2006); comparison with normotensive
infants is clearly inappropriate. No randomized control study
to explore effects of inotropic medications has been reported
with untreated hypotensive infants as the control group, due
to the obvious ethical concerns as mentioned above. Carefully
designed research is needed to determine the long-term impact
of different approaches to the treatment of neonatal hypotension
and use of inotropic agents. Randomization of patients with
hypotension but without clinical or laboratory evidence of
cardiovascular compromise to have no inotropic treatment (per-
missive hypotension) (Dempsey et al., 2009) is a potential means
to address the issue. Despite the application of preterm animal
models to investigate preterm cerebral physiology and pathology,
there have been no studies investigating the relationship between
maintenance and/or increase of CBF with the administration
of inotropes, to the neurological outcomes and histopathology
in the developing brain. Such research is imperative given the
widespread clinical use of inotropic medications in preterm
infants, coupled with the scarce knowledge of its effects on the
immature brain. Utilizing immature animal models to study
and relate the neurophysiological and histopathological effects
of inotropic therapy would fill this current knowledge gap and
potentially influence clinical practice.
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